Start-Up Nation Poised To Corner the Global Medical Marijuana Market

Image by File
Medical marijuana is on track to become a booming industry in Israel, with 36 Israeli companies now doing clinical research on cannabis, according to a report in the Economist.
That figure comes from Saul Kaye, the CEO of the venture fund and technology incubator iCAN.
Israel’s health ministry is licensing a list of about 100 doctors to prescribe the drug, and regular pharmacists will be able to stock it.
What’s more, in August, the agriculture minister announced that local growers will soon be allowed to export their crop.
There’s a reason why medical marijuana research is blossoming in Israel, even though the country’s right wing government is against legalization of marijuana for recreational use.
Israel’s strong agricultural and medical sectors, combined with its reputation as “startup nation” have primed it for developing marijuana for medical use.
What’s more, wrote the Economist, it has a 60-year head start on the United States where marijuana research is just beginning.
While the United States is just beginning to review laws that hamper research with an eye to possibly changing them, Israeli scientists have been looking into the topic for decades. Raphael Mechoulam, considered the father of cannabis research, is an Israeli professor at the Hebrew University of Jerusalem.
Israel researchers are looking into uses of medical marijuana for a range of conditions beyond pain relief, such as Alzheimer’s disease and Tourette’s syndrome.
Contact Naomi Zeveloff at [email protected] or on Twitter @naomizeveloff
The Forward is free to read, but it isn’t free to produce

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
This is a great time to support independent Jewish journalism you rely on. Make a gift today!
— Rachel Fishman Feddersen, Publisher and CEO
Support our mission to tell the Jewish story fully and fairly.
Most Popular
- 1
Opinion The dangerous Nazi legend behind Trump’s ruthless grab for power
- 2
Opinion A Holocaust perpetrator was just celebrated on US soil. I think I know why no one objected.
- 3
Culture Did this Jewish literary titan have the right idea about Harry Potter and J.K. Rowling after all?
- 4
Opinion I first met Netanyahu in 1988. Here’s how he became the most destructive leader in Israel’s history.
In Case You Missed It
-
Culture Trump wants to honor Hannah Arendt in a ‘Garden of American Heroes.’ Is this a joke?
-
Opinion Gaza and Trump have left the Jewish community at war with itself — and me with a bad case of alienation
-
Fast Forward Trump administration restores student visas, but impact on pro-Palestinian protesters is unclear
-
Fast Forward Deborah Lipstadt says Trump’s campus antisemitism crackdown has ‘gone way too far’
-
Shop the Forward Store
100% of profits support our journalism
Republish This Story
Please read before republishing
We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:
- Credit the Forward
- Retain our pixel
- Preserve our canonical link in Google search
- Add a noindex tag in Google search
See our full guidelines for more information, and this guide for detail about canonical URLs.
To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.